JAGX · Jaguar Health, Inc.

Jaguar Health's 2025 financial results show a deteriorating bottom line despite relatively stable revenue. The company's net loss widened significantly to $53.6 million from $38.5 million in 2024, primarily driven by increased operating expenses across multiple categories. Research and development costs surged by $8.4 million to $25.0 million, largely due to clinical and manufacturing expenses for crofelemer lyophilization and clinical trial data that had no alternative future use. Sales and marketing expenses rose by $1.5 million to $9.2 million, attributed to personnel costs for the Gelclair sales team, while general and administrative expenses increased by $2.3 million to $18.6 million due to legal and compliance expenses from licensing activities, printing costs, investor relations, and financing activities. The company also recognized an $0.8 million impairment loss on indefinite-lived intangible assets resulting from delays in IBS and PEDS programs. Revenue performance was mixed, with total net revenue of $11.5 million in 2025 representing a slight decrease from $11.7 million in 2024. Notably, $11.2 million of the 2025 revenue came from sales of Mytesi and Canalevia-CA1, but the company has now shifted commercial responsibility for these products to Future Pak under a January 2026 license agreement that provided $16 million in up-front non-dilutive capital. The company faces regulatory challenges with Nasdaq noncompliance and will appeal the determination at a hearing on April 7, 2026, with delisting stayed pending the panel's decision. Jaguar's strategy appears focused on concentrating crofelemer development efforts on human rare-disease intestinal failure indications while monetizing existing commercial products through licensing arrangements.